JAMA Review Time

JAMA held flat at 55.0 from 2023 to 2024 after the pandemic citation spike fully normalized. That steady year-over-year picture matters because it shows the flagship is back on its structural baseline rather than drifting downward in general medicine.

JAMA requires a structured abstract with specific sections (Importance, Objective, Design, Setting, Participants, Exposures/Interventions, Main Outcomes, Results, Conclusions and Relevance). Editors use this structure to triage. If the structured abstract doesn't work, the paper doesn't get read further.

Like NEJM and the Lancet, JAMA has its own statistical reviewers. They evaluate methodology independently of the clinical peer reviewers. This means statistical concerns surface earlier and more consistently than at journals that rely on reviewer-provided statistical assessment.

JAMA sits atop a network of 10+ specialty journals (JAMA Oncology, JAMA Cardiology, JAMA Internal Medicine, JAMA Neurology, etc.). When editors reject a paper that has merit but isn't broad enough for the flagship, they often offer to transfer it within the network. This transfer includes the editor's notes and sometimes reviewer reports, which can speed up the process at the receiving journal.

Fast desk rejection (1-2 weeks): The clinical question isn't broad enough for JAMA's general physician readership. The most common outcome.

Transfer offer (2-3 weeks): The editors like the work but think it fits a JAMA Network specialty journal better. Take this seriously. JAMA Oncology, JAMA Cardiology, and JAMA Internal Medicine are top-tier journals in their own right.

Review completed in 6-8 weeks: Standard. The concurrent statistical review adds time but makes the decision more comprehensive.

Revision requiring AMA citation style corrections: Common for authors unfamiliar with JAMA's specific formatting requirements. AMA style from day one saves a revision round.

JAMA timing is only one piece of the editorial reality. The harder question is usually whether the paper belongs in the flagship or whether a JAMA Network specialty journal would be the cleaner fit from the start. That distinction matters because the same 6-10 week review window can either represent serious all-of-medicine scrutiny or unnecessary delay for a paper that was always specialty-specific.

For authors, that is the practical lesson behind the timeline. A slower flagship process is often worth it only when the manuscript really has general clinical reach. If the true audience is oncology, neurology, cardiology, or pediatrics, the extra weeks can be a sign that the paper is being tested against a broader readership than it actually needs.

At JAMA, time in review often reflects breadth testing more than pure methodological delay. Reviewers and editors are asking whether the study changes practice outside one specialty and whether non-specialist physicians can understand why the result matters. That makes the waiting period more informative than many authors realize. A paper that is scientifically strong but framed too narrowly may still survive peer review, but the process often becomes slower because editors are trying to decide whether the flagship audience is genuinely right.

That is why the most useful preparation during the wait is not generic rebuttal drafting. It is clarifying the paper's broad clinical sentence: what a general physician should do differently, what kind of patient or care setting is affected, and why this is not merely a subspecialty update. If that sentence is weak, the review timeline is telling you something important about target fit.

Use the timeline together with the surrounding cluster, not in isolation:

• JAMA submission guide
• JAMA submission process
• JAMA impact factor
• JAMA pre-submission checklist
• JAMA under review
• How to avoid desk rejection at JAMA
• Is JAMA a good journal?

In our pre-submission review work on JAMA-targeted manuscripts, the slow or unsuccessful files are usually not the ones with weak methods. They are the ones where the broad clinical consequence is still doing too much hidden work.

The flagship vs specialty-journal call is still unresolved. JAMA can move quickly when the paper obviously matters to physicians outside one specialty. When the real audience is oncology, cardiology, or neurology and the broad framing sits mostly in the cover letter, editors spend more time deciding whether to transfer or stop the process.

The structured abstract is informative but not decision-oriented enough. JAMA's abstract format forces clarity, but it does not rescue a manuscript that still ends at "this finding is important." We see faster positive outcomes when the abstract names what a physician, system leader, or policymaker should understand differently after reading the paper.

Statistical polish lags behind the clinical claim. This journal's internal biostatistical review means the endpoints, subgroup logic, and limitations language have to look finished before submission. A paper that still feels statistically arguable tends to turn one review round into two.

We see the fastest positive outcomes when the manuscript makes the broad clinical sentence obvious in the title, abstract, and first figure rather than saving it for the discussion. That is usually the difference between a paper that reads like flagship JAMA and one that still belongs in the network.

Published timelines are medians that can mask real variation. Desk rejections (often 1-3 weeks) skew the median down, making the number shorter than what reviewed papers actually experience. Seasonal effects (December submissions sit longer, September backlogs) and field-specific reviewer availability also affect your specific wait time. The timeline does not include acceptance-to-publication time.

A JAMA desk-rejection risk check scores fit against the journal's editorial bar.